Effect of Brivaracetam in Photosensitive Epileptic Subjects

Phase 2

Completed

• Conditions: Epilepsy

• Registration Number: NCT00401648
• Lead Sponsor: UCB Pharma

Brief Summary

to assess the effect of brivaracetam on the photoparoxysmal EEG response in photosensitive epileptic subjects

Detailed Description

Not available

Study Timeline

• Study Start: 2002-09
• Primary Completion: 2003-06
• Study Completion: 2003-06
• Study First Submitted: 2006-11-17
• Study First Submitted QC: 2006-11-17
• Study First Posted: 2006-11-20
• Status Verified: 2009-11
• Last Update Submitted: 2009-11-30
• Last Update Posted: 2009-12-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• epileptic subjects with generalized PPR

Exclusion Criteria

• more than 2 concomitant antiepileptic drugs

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Identify lowest single oral dose producing maximal decrease or suppression of intermittent photic stimulation (IPS)photoparoxysmal response (PPR) in photosensitive epileptic subjects pre-dose
post placebo during 24h and post brivaracetam for up to 72 h

Secondary Outcome Measures

Name	Time	Method
Assess relationship between plasma concentrations and changes in photosensitivity frequency range, time of onset and duration of suppressing effect
Safety